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Abstract9
Rinderpest is an acute, highly contagious often fatal disease of large and small ruminants, both domestic and wild. Global eradication
of rinderpest needs a robust, safe and cost-effective vaccine. The causative agent, rinderpest virus (RPV) is an important member of
the genus Morbillivirus in the Paramyxoviridae family. We have generated transgenic peanut (Arachis hypogea L.) plants expressing
hemagglutinin protein of RPV and report here, the induction of immune responses in cattle following oral feeding with transgenic
leaves expressing hemagglutinin protein without oral adjuvant. Hemagglutinin-specific antibody was detected in the serum as confirmed
by immunohistochemical staining of virus-infected cells, and in vitro neutralization of virus infectivity. Oral delivery also resulted in
cell-mediated immune responses.
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1. Introduction20
Rinderpest is an acute, febrile, highly contagious disease21
of cattle caused by rinderpest virus (RPV), which is a mem-22
ber of the family Paramyxoviridae and genus Morbillivirus.23
In spite of availability of a highly effective live attenuated24
vaccine, rinderpest remains a threat to livestock in develop-25
ing countries. The difficulty in maintaining the cold chain re-26
sults in failure of vaccination in the hot regions where rinder-27
pest is endemic. Attempts have been made to develop heat28
stable rinderpest vaccines, which include thermostable Vero29
cell-adapted rinderpest vaccine [1,2], Xerovac live attenu-30
ated rinderpest vaccine [3] and dry powder rinderpest vac-31
cine [4]. RPV contains two glycoproteins, hemagglutinin (H)32
and fusion (F) proteins, on its host cell membrane-derived33
envelope. H and F proteins are known to be highly immuno-34
genic and confer protective immunity. Efforts have been35
made to develop recombinant vaccinia virus expressing H36
and F [5–9] and recently long-term immunity in cattle has37
also been demonstrated [10,11]. Because of its wide host38
range, the use of recombinant vaccinia virus remains a mat-39
ter of debate. Another pox virus (capripox virus), which has40
more restricted host range, has been used to develop recom-41
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binant capripox–rinderpest virus vaccine [12,13] and vac- 42
cination with this vaccine confers long-term immunity in 43
African cattle [14]. Further, the H and F proteins expressed 44
by recombinant baculo virus was shown to be immunogenic 45
[15] and a recombinant baculo virus expressed H protein 46
could induce both humoral and cell-mediated immune re- 47
sponse [16,17]. In addition, the recombinant H expressed 48
as extracellular baculo virus particles has been shown to 49
elicit cytotoxic T-cell responses and a CTL epitope on H has 50
been mapped [18,19]. Although the above-mentioned efforts 51
promise to provide an effective vaccine, their use becomes 52
prohibitively expensive because of the cost of production of 53
cell culture vaccine. 54
In order to effectively control and eliminate rinderpest, 55
a vaccine is necessary which provides a handle to differ- 56
entiate between animals that have been vaccinated and 57
those, which have recovered from natural infection [20]. 58
For pathogens, which enter and colonize in the mucosal 59
epithelium of gastrointestinal, respiratory and genital tract, 60
it would be better to employ a mucosal vaccine since in- 61
duction of both mucosal and systemic immune responses is 62
achieved whereas the reverse does not hold true. A recombi- 63
nant subunit vaccine expressed in edible parts of transgenic 64
plants promises to possess the desired properties. In case 65
of foot and mouth disease and transmissible gastroenteritis, 66
recombinant antigens expressed in transgenic plants have 67
been reported to possess immunological properties at least 68
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in the mouse model [21,22]. We have recently shown that69
the H protein of RPV expressed in a model plant, tobacco is70
immunogenic and elicit specific humoral immune response71
[23]. Further, we have expressed the hemagglutinin protein72
in transgenic peanut, a crop which is also used in India73
for animal feeding after harvesting the nuts, and tested its74
antigenicity and immunogenicity. This peanut-derived H is75
immunologically active when delivered through parenteral76
or through oral route in experimental mouse model system77
(Khandelwal et al., submitted for publication). In the present78
communication, we report the induction of specific immune79
responses in cattle upon oral feeding with transgenic leaves80
of peanut expressing H without mucosal adjuvant.81
2. Materials and methods82
2.1. Animals83
Four cattle (C1–C4) were maintained at the Central Ani-84
mal Facility of the Institute. C1, C2 and C4 (4–5 years age)85
of Holstein–Friesian cross-breed and C3 (about 2–3 years86
age) is a Jersey breed.87
2.2. Cells and viruses88
Vero cells were obtained from National Center for Cell89
Science, Pune, India and were maintained in MEM sup-90
plemented with 5% fetal calf serum (Gibco-BRL, USA) at91
37 ◦C in a CO2 incubator. A tissue culture adapted vaccine92
strain of RPV (RBOK) [24] was obtained from the Institute93
of Animal Health and Veterinary Biologicals, Bangalore, In-94
dia and vaccine strain of PPRV (Nig 75/1) was provided by95
Dr. A. Diallo, CIRAD-EMVT, France. To prepare infected96
cell lysates, at 24–48 h post-infection of Vero cells when97
70% CPE was seen, cells were lysed in PBS by freezing and98
thawing three times and stored at −20 ◦C till further use.99
2.3. Recombinant proteins100
Recombinant hemagglutinin protein expressed in insect101
cells secreted into the medium (SecH) was used [25]. Re-102
combinant nucleocapsid protein of RPV expressed in E.103
coli was purified by CsCl gradient as described earlier [26].104
The full length M gene of RPV (RBOK) was cloned into105
pBluesript KS+ vector (kindly provided by Dr. M. Baron,106
Institute for Animal Health, Pirbright, UK) was subcloned107
into pRSET expression vector and expressed in E. coli108
BL21 (DE3) (Shaji and Shaila, unpublished data), as His109
tag protein. The protein was purified on a nickel affinity110
column.111
2.4. Antibodies112
A mouse monoclonal antibody D2F4 to RPV H protein113
earlier generated in the laboratory [27] was used. Polyclonal114
monospecific antibodies to RPV H purified from infected 115
cell extracts were generated in rabbits [28]. 116
2.5. Transgenic peanut plants 117
The hemagglutinin gene of attenuated strain (RBOK) of 118
rinderpest virus was subcloned into binary vector pBI 121. 119
In the recombinant binary vector pBI H, the H gene is un- 120
der the control of constitutively expressed CaMV 35S pro- 121
moter. pBI H was mobilized into Agrobacterium tumefaciens 122
(EHA 105). Transgenic peanut plants obtained using pBI 123
121 served as the control and termed as vector-transformed 124
peanut plants. Transgenic peanut plants expressing hemag- 125
glutinin protein were generated via Agrobacterium-mediated 126
transformation of shoot apices (Khandelwal et al., submit- 127
ted for publication). Total protein from leaves was isolated 128
employing the method of McGarvey et al. [29] used for the 129
solubilization of rabies virus glycoprotein. The expression 130
level of H was in the range of 0.2–1.3% of total soluble 131
protein as estimated by double antibody sandwich ELISA 132
using a standard curve where recombinant H was used as 133
an antigen. Leaves from different lines expressing H were 134
pooled and fed to the animals such that each dose con- 135
tained an amount of H equivalent to 0.5% of total soluble 136
protein. 137
2.6. Immunization schedule 138
The animals were fed with either transgenic peanut leaves 139
expressing H (C2–C4) or with vector-transformed peanut 140
leaves (C1) as control at weekly interval for three consecu- 141
tive weeks. The first immunization was with about 7.5 g of 142
leaves followed by 5 g of leaves at 7 and 14 days. Animals 143
were given normal feed at all times. 144
2.7. Competition ELISA 145
The method described by Anderson and McKay [30] was 146
used. The assay was performed in a 96-well flat bottom plate. 147
SecH was used as the antigen (1:150 dilution in PBS) and 148
D2F4 monoclonal antibody (1:5000) was used for competi- 149
tion with test serum. The reaction was developed with 50l 150
of OPD (4 mg/ml) and H2O2 (2l of 30% stock) in PBS af- 151
ter terminating the reaction with 50l of 2N H2SO4, plate 152
was read at 490 nm in an ELISA reader, which is attached 153
to a computer having enzyme immunoassay (EIA) software 154
of Biologicals Diagnostic mSupplies Ltd. (BDSL) and the 155
OD values were converted to percentage inhibition (PI) val- 156
ues. Percentage inhibition more than 40 was considered to 157
be significant. 158
2.8. Immunohistochemical staining 159
The method described by Naik et al. [16] was used to 160
test the immune sera for reactivity with RPV H made in 161
virus-infected cells. 162
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2.9. Virus neutralization test163
Serum samples collected at various time points were164
tested for the presence of neutralizing antibodies (both165
homologous and cross-neutralizing) in triplicates using166
flat-bottomed 96-well plates as described by Barrett et al.167
[6]. Attenuated strain of RPV (RBOK strain) and vaccine168
strain of PPRV Nig 75/1 were grown on Vero cells and169
titrated employing TCID50 method [31]. Pooled serum170
samples (for each bleed, serum was pooled from all the five171
mice of the group) were heat inactivated at 56 ◦C for 30 min172
and then double diluted with culture medium, starting from173
an initial dilution of 1:20. Following incubation with 100174
TCID50 of virus at 37 ◦C for 1 h, 2× 104 cells were added175
to each well. The wells without the sera/virus served as176
control. The plates were monitored for 5–7 days for cyto-177
pathic effects (CPE) for RPV and 3–5 days for PPRV. Virus178
neutralization titer was defined as the highest dilution of179
the sera, which inhibited CPE by 50%.180
2.10. In vitro lymphoproliferation181
Animals were bled through jugular vein puncture at spec-182
ified times. The blood was diluted 1:2 in sterile PBS and183
was subjected to Ficoll–Hypaque (Pharmacia) density cen-184
trifugation at 3000 rpm for 30 min. The buffy coat was col-185
lected and diluted in excess PBS. The cells were recovered186
by centrifugation and washed and resuspended in RPMI187
1640 supplemented with 10% FBS (Gibco-BRL, USA). The188
lymphocytes were proliferated in triplicates at a density of189
2× 105 cells per well in presence of varying concentrations190
of SecH, N, M proteins or PPRV infected cell lysate or un-191
infected cell lysate in a final volume of 200l per well for192
5 days. The cells were pulsed with 1Ci [3H]-thymidine193
(specific activity 6500 mCi/mmol; Amersham) for 16 h and194
harvested on glass fiber filter (Nunc, USA). The incorpo-195
rated radioactivity was measured in a Rackbeta scintillation196
spectrometer.197
Fig. 1. Competition of immunized cattle serum with monoclonal antibody for recombinant H protein. Percent inhibition is calculated using the formula:
PI = 100 − [(OD in test well/OD in 0% control well)] × 100. C1–C4 are represented as follows: C1 (), C2 (), C3 ( ) and C4 ( ).
3. Results 198
3.1. Humoral immune responses 199
Animals were bled at regular intervals after immuniza- 200
tion either with transgenic peanut leaves expressing H or 201
vector-transformed peanut leaves and sera were examined 202
for the presence of H-specific serum antibodies in ELISA 203
using recombinant secretory form of H (SecH) in a competi- 204
tion ELISA. Inhibition of binding to H protein of monoclonal 205
antibody (D2F4) generated against RPV H by immune sera 206
(Fig. 1) demonstrates the specificity of antibody. The serum 207
from immunized animal, which received transgenic peanut 208
expressing H competed very well with the monoclonal an- 209
tibody and no significant competition was seen in presence 210
of serum from the cattle fed with vector-transformed peanut 211
leaves. 212
The specificity of the antibody produced in response to 213
oral delivery of recombinant H as part of food was also ver- 214
ified by immunostaining of the infected cells. When anti- 215
bodies from the orally fed animals were used for reactivity 216
with antigens expressed in virus-infected cells only the im- 217
munized cattle serum reacted with viral antigen expressed 218
in infected cells and the immune serum from the control 219
animal that was fed with vector-transformed peanut leaves 220
did not show any reactivity (Fig. 2) suggesting the capabil- 221
ity of induced antibodies to recognize the antigens made by 222
infected cells. 223
3.2. In vitro neutralization of virus infectivity 224
To analyze the in vitro protective ability of the induced 225
antibodies, virus neutralization test was performed. Results 226
(Tables 1 and 2) clearly show that high levels of neutral- 227
izing and cross-neutralizing antibodies are present in the 228
serum 1 week after immunization and are maintained up 229
to the duration of the experiments in the orally immunized 230
animals. Homologous and heterologous virus neutraliz-
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Fig. 2. Immunohistochemical staining. Panel A: uninfected Vero cells. Panels B and C: infected Vero cells immunostained with preimmune and immune
serum (1:50 dilution in PBS) from animal fed with vector-transformed leaves (C1), respectively. Panels D and E: infected Vero cells stained with
preimmune and immune serum (1:50 dilution in PBS) from animal fed with transgenic peanut leaves (C4), respectively. Vero cells grown on coverslips
were infected with RPV (RBOK) at a multiplicity of 0.1–0.5 and incubated at 37 ◦C, for 48–72 h till 30–40% CPE was seen. Coverslips were washed
in PBS and cells were fixed for immunohistochemical staining.
ing ability was absent in serum from the animal fed with231
vector-transformed peanut leaves. Earlier work from our232
group on virus neutralization titer following vaccination233
had shown virus neutralization titers of 20, 40, 40, 160 at234
1, 2, 4 and 8 weeks post-immunization and nearly twofold235
lower titers of cross-neutralization against PPRV [17]. How-236
ever, immunization of cattle with recombinant baculovirus237
expressing H (rECV-H) resulted in a twofold higher titer238
for both homologous and heterologous virus neutralization239
titers. Induction of high levels of virus neutralization titer240
immediately at 1 week post-immunization could be due241
to the adjuvant activity provided by some plant compo-242
nent. These results demonstrate that antibodies generated243
upon oral immunization are able to provide protection244
against RPV or cross-protection against PPRV infections 245
in vitro. 246
3.3. Lymphoproliferative responses 247
At the end of 10th week post-immunization, PBMC were 248
isolated and used for in vitro proliferation assay in pres- 249
ence of recombinant antigens (Fig. 3A and B ). PBMC 250
from animals fed with transgenic peanut leaves expressing 251
H proliferated in a dose-dependent manner when SecH was 252
used as the antigen (Fig. 3A), and the animal (C1) fed with 253
vector-transformed peanut leaves did not show any prolif- 254
eration in response to SecH. The specificity of lymphopro- 255
liferative responses was tested by stimulating the PBMC in 256
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Table 1
In vitro neutralization of RPV infectivity by serum collected from cattle
after oral immunization with transgenic peanut leaves or with vector-
transformed peanut leaves
Animal Virus neutralization titera (days post-immunization)
0 7 14 21 28 35 42 49 56 63 70
C1 0 0 0 0 0 0 0 0 0 0 0
C2 0 320 320 640 80 40 40 40 40 40 20
C3 0 640 640 320 160 160 160 160 80 40 20
C4 0 160 320 320 160 160 160 40 40 40 40
a Virus neutralization titer is defined as the reciprocal of the highest
dilution of serum exhibiting 50% protection of infected cells.
presence of other antigens of RPV. Data shown in Fig. 3B257
shows that lymphocytes from orally immunized animals do258
not respond to other antigens of RPV (nucleocapsid (N)259
protein and matrix (M) protein). Although the lymphocytes260
from vaccinated animal have been shown to proliferate in261
response to N protein of RPV [18]. In addition, when the262
cross-reactive proliferative responses to PPRV antigens were263
tested (Fig. 3C), lymphocytes from the animal immunized264
with peanut-derived H proliferated well in vitro in presence265
of PPRV infected cell lysate and the animal that received266
vector-transformed peanut leaves did not respond.267
4. Discussion268
As part of efforts to develop edible vaccine for rinder-269
pest, we generated transgenic peanut (Arachis hypogea L.)270
plants expressing hemagglutinin protein of rinderpest virus.271
The antigenicity of peanut-derived H protein was established272
using specific antibodies and its immunogenicity was ana-273
lyzed in a mouse model (Khandelwal et al., submitted for274
publication). Oral feeding of transgenic peanut leaves in-275
duced specific mucosal (secretory IgA) and systemic im-276
mune responses (serum IgG and IgA) and also cell-mediated277
immune responses. In the present work, induction of im-278
mune responses in cattle was monitored upon oral deliv-279
ery of hemagglutinin protein of rinderpest virus as part of280
food, without any mucosal adjuvant. To our knowledge, this281
is the first report describing elicitation of specific immune282
responses in the host animal by a protective antigen of a283
Table 2
In vitro neutralization of PPRV infectivity by serum collected from cattle
after oral immunization with transgenic peanut leaves or with vector-
transformed peanut leaves
Animal Virus neutralization titera (days post-immunization)
0 7 14 21 28 35 42 49 56 63 70
C1 0 2 2 2 2 2 4 2 2 0 0
C2 0 128 256 256 256 64 32 32 32 32 8
C3 0 0 0 0 0 64 128 128 64 64 16
C4 0 128 256 256 64 64 64 32 32 16 8
a Virus neutralization titer is defined as the reciprocal of the highest
dilution of serum exhibiting 50% protection of infected cells.
Fig. 3. (A) Lymphoproliferation of PBMC from animals fed with ei-
ther vector-transformed peanut leaves (C1) or with transgenic peanut
leaves (C2–C4) at 10 weeks post-immunization in presence of recombi-
nant hemagglutinin protein. (B) Lymphoproliferation of PBMC from C1
(control animal fed with vector-transformed peanut leaves) and C4 (fed
with transgenic peanut leaves expressing H) in presence of nucleocapsid
(N) and matrix (M) protein of RPV. (C) In vitro proliferation of PBMC
from C1 () and C4 () in presence of antigens of PPRV.
Morbillivirus expressed in transgenic plants given orally. 284
Although small quantities of transgenic plant tissues (7.5 g 285
for the first feeding followed by two feedings of 5 g) was 286
given orally, the test animals developed high titer of spe- 287
cific antibodies. These antibodies were able to compete out 288
monoclonal antibodies in ELISA (Fig. 1) demonstrating the 289
specificity of the induced antibodies; in addition, these an- 290
tibodies neutralized the virus infectivity in vitro. Animals 291
were fed only thrice with plant-derived antigen at weekly 292
intervals, which in addition to production of significant lev- 293
els of specific antibody, resulted in stimulation of T cells 294
from immunized animals in response to specific antigens 295
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(Fig. 3A and B) indicating the induction of systemic immune296
response upon oral immunization. Wigdorovitz et al. [21]297
reported induction of protective systemic immune response298
in the mouse model upon oral feeding of transgenic plants299
expressing VP1 protein of foot and mouth disease virus. In300
this work, the VP1 protein expressed in alfalfa plants was301
not detected by Western blotting and several immunizations302
(three times a week for 2 months with approximately 0.3 g303
of leaves) were needed in order to induce a significant im-304
mune response. Similarly, Gomez et al. [22] have shown oral305
immunogenicity of the spike protein of swine-transmissible306
gastroenteritis coronavirus expressed in potato in a mouse307
model. This group followed almost similar immunization308
schedule as reported by Wigdorovitz et al. [21]. However,309
there was no detectable neutralization activity, which was310
attributed to the post-translational processing in the host311
plant. Compared to these two reports, in the present work,312
small quantities of peanut expressed H protein given orally313
without adjuvant induced high levels of virus neutralizing314
antibodies.315
There are two reports where induction of specific immune316
response is demonstrated upon oral feeding of human vol-317
unteers with potato tubers expressing LT-B of E. coli [32] or318
Norwalk virus capsid protein-assembled as virus like parti-319
cles [33]. In the first human trials, the antigen used (LT-B)320
is a well-known mucosal adjuvant and therefore when given321
through oral route, LT-B antigen induced significant sys-322
temic and mucosal immune responses. In the second trial,323
potato expressing Norwalk virus capsid protein was deliv-324
ered orally. It has been suggested that the particulate na-325
ture of the virus like particles confer greater stability to the326
antigen in the stomach and resulted in specific immune re-327
sponse although the level of specific serum antibody was328
modest. Induction of specific immune response in mice upon329
oral delivery of measles virus hemagglutinin expressed in330
plant tissues has been demonstrated [34]. The induction of331
immune responses upon oral delivery shown in the present332
work might be due to “bioencapsulation” as described by333
Kong et al. [35]. Modelska et al. [36] have shown that ex-334
pressed antigen is more immunogenic when plant material335
is fed orally as compared to the plant proteins present in336
the extract. Additionally, there is evidence to suggest that337
components of the plant also influence the immunogenicity338
of the antigen expressed [22]. The induction of serum or339
mucosal antibody response to orally administered antigens340
is often difficult and generally requires large quantities of341
antigen as only part of the antigen is being absorbed and342
is capable of eliciting an immune response. It was assumed343
that co-administration of a mucosal adjuvant is necessary344
to achieve optimum oral immunogenicity for a given anti-345
gen. Furthermore, the presentation of large amount of anti-346
gen may lead to oral tolerance and use of mucosal adjuvant347
will result in non-specific stimulation of mucosal immune348
system. de Aizpurua and Russell-Jones [37] have identified349
the class of proteins that provoke an immune response upon350
oral feeding and concluded that all the proteins that possess351
“lectin or lectin-like” binding activities are active in oral im- 352
munization. These molecules have the ability to bind to gly- 353
colipids or glycoproteins on the intestinal mucosae and thus 354
transported across the epithelial barrier, to enter the circu- 355
lation and elicit an immune response. More recently, plant 356
lectins with different sugar specificities have been investi- 357
gated for mucosal immunogenicity [38] and elicitation of 358
specific systemic and mucosal antibody response was ob- 359
served upon intranasal or oral administration. Since hemag- 360
glutinin protein of RPV is a cell attachment protein which 361
binds to cell surface oligosaccharide containing protein or 362
glycoconjugate in order for the virus to begin the infection 363
process, it qualifies to be in the categories of antigens hav- 364
ing “lectin or lectin-like” activities. Therefore, it is conceiv- 365
able that H protein may be transported across the epithelial 366
barrier easily through the mechanism described by Lavelle 367
et al. [38] and leading to systemic immune responses. It re- 368
mains to be seen if this protein expressed in peanut plants 369
elicits a mucosal immune response upon oral immunization. 370
Rinderpest is an economically important disease of live- 371
stock and certainly remains a threat to the world because 372
of the isolated foci of the disease. History has witnessed 373
the outbreak of the disease after 40 years of rinderpest-free 374
Sri Lanka [39]. Since most part of the world is declared 375
rinderpest-free, use of time tested live attenuated vaccine is 376
restricted. And the infection cannot be diagnosed at an early 377
stage since there is no simple test to differentiate between 378
animals vaccinated with currently used vaccine and infected 379
animals. The recombinant subunit oral vaccine expressed in 380
plants is useful not only in differentiating vaccinated and in- 381
fected animals but also offers a cost-effective means of mass 382
vaccination by production of transgenic plants expressing the 383
vaccine antigen in developing countries. In addition, it will 384
have the advantage provided by an oral vaccine which re- 385
sults in induction of both mucosal and systemic immune re- 386
sponses better achieved through oral administration as com- 387
pared to parenteral delivery of the antigen and may help in 388
the first line of defense at the mucosal surfaces. Although 389
we have not carried out any challenge experiments due to 390
lack of high disease security and containment facilities, in 391
vitro neutralization demonstrated the protective capability 392
of the induced antibodies and priming of T cells, which are 393
also involved in rinderpest immunity [15] and therefore the 394
present work clearly demonstrates the potential of edible 395
oral vaccine against rinderpest. 396
Acknowledgements 397
We acknowledge the help of Dr. G.J. Renukaradhya in 398
animal experiments. A.K. was a Senior Research Fellow of 399
Council of Scientific and Industrial Research (CSIR), Gov- 400
ernment of India. We acknowledge the infrastructural facil- 401
ities provided by the Department of Biotechnology, Gov- 402
ernment of India, under the program support for infectious 403
diseases. 404
UN
CO
RR
EC
TE
D 
PR
OO
F
A. Khandelwal et al. / Vaccine 3812 (2003) 1–8 7
References405
[1] Mariner JC, van den Ende MC, House JA, Mebus CA, Salifou S,406
Stem C. The serological response to a thermostable Vero cell-adapted407
rinderpest vaccine under field conditions in Niger. Vet Microbiol408
1990;22:119–27.409
[2] Mariner JC, House JA, Sollod AE, Stem C, van den Ende MC, Mebus410
CA. Comparison of the effect of various chemical stabilizers and411
lyophilization cycles on the thermostability of a Vero cell-adapted412
rinderpest vaccine. Vet Microbiol 1990;21:195–209.413
[3] Worrall EE, Litamoi JK, Seck BM, Ayelet G. Xerovac: an414
ultra rapid method for the dehydration and preservation of live415
attenuated rinderpest and peste des petits ruminants vaccines. Vaccine416
2000;19:834–9.417
[4] Anderson J, Fishbourne E, Corteyn A, Donaldson AI. Protection418
of cattle against rinderpest by intranasal immunisation with a dry419
powder tissue culture vaccine. Vaccine 2000;22:840–3.420
[5] Yilma T, Hsu D, Jones L, Owens S, Grubman M, Mebus C,421
et al. Protection of cattle against rinderpest with vaccinia virus422
recombinants expressing the H or F gene. Science 1988;242:1058–423
61.424
[6] Barrett T, Belsham GJ, Subbarao SM, Evans SA. Immunization with425
a vaccinia recombinant expressing the F protein protects rabbits426
from challenge with a lethal dose of rinderpest virus. Virology427
1989;170:11–8.428
[7] Belsham GJ, Anderson EC, Murray PK, Anderson J, Barrett T.429
Immune response and protection of cattle and pigs generated by a430
vaccinia virus recombinant expressing the F protein of rinderpest431
virus. Vet Rec 1993;124:655–8.432
[8] Giavedoni L, Jones L, Mebus C, Yilma T. A vaccinia virus double433
recombinant expressing the F and H genes of rinderpest virus protects434
cattle against rinderpest and causes no pock lesions. Proc Natl Acad435
Sci USA 1991;88:8011–5.436
[9] Yamanouchi K, Inui K, Sugimoto M, Asano K, Nishimaki F, Kitching437
RP, et al. Immunisation of cattle with a recombinant vaccinia vector438
expressing the haemagglutinin gene of rinderpest virus. Vet Rec439
1993;132:152–6.440
[10] Ohishi K, Inui K, Barrett T, Yamanouchi K. Long-term protective441
immunity to rinderpest in cattle following a single vaccination with442
a recombinant vaccinia virus expressing the virus haemagglutinin443
protein. J Gen Virol 2000;81(Part 6):1439–46.444
[11] Verardi PH, Aziz FH, Ahmad S, Jones LA, Beyene B, Ngotho RN, et445
al. Long-term sterilizing immunity to rinderpest in cattle vaccinated446
with a recombinant vaccinia virus expressing high levels of the fusion447
and hemagglutinin glycoproteins. J Virol 2002;76:484–91.448
[12] Romero CH, Barrett T, Evans SA, Kitching RP, Gershon PD,449
Bostock C, et al. Single capripox recombinant vaccine for the450
protection of cattle against rinderpest and lumpy skin disease. Vaccine451
1993;11(7):737–42.452
[13] Romero CH, Barrett T, Chamberlain RW, Kitching RP, Fleming M,453
Black DN. Recombinant capripox virus expressing the hemagglutinin454
protein of rinderpest virus: protection of cattle against rinderpest and455
lumpy skin disease viruses. Virology 1994;204(1):425–9.456
[14] Ngichabe CK, Wamwayi HM, Ndungu EK, Mirangi PK, Bostock CJ,457
Black DN, et al. Long-term immunity in African cattle vaccinated458
with a recombinant capripox–rinderpest virus vaccine. Epidemiol459
Infect 2002;128:343–9.460
[15] Bassiri M, Ahmad S, Giavedoni L, Jones L, Saliki JT, Mebus C, et al.461
Immunological responses of mice and cattle to baculovirus-expressed462
F and H proteins of rinderpest virus: lack of protection in the presence463
of neutralizing antibody. J Virol 1993;67:1255–61.464
[16] Naik S, Renukaradhya GJ, Rajasekhar M, Shaila MS. Immunogenic465
and protective properties of haemagglutinin protein (H) of466
rinderpest virus expressed by a recombinant baculovirus. Vaccine467
1997;15(67):603–7.468
[17] Sinnathamby G, Naik S, Renukaradhya GJ, Rajasekhar M, Nayak R,469
Shaila MS. Recombinant hemagglutinin protein of rinderpest virus470
expressed in insect cells induces humoral and cell-mediated immune 471
responses in cattle. Vaccine 2001;19:3870–6. 472
[18] Sinnathamby G, Renukaradhya GJ, Rajasekhar M, Nayak R, 473
Shaila MS. Recombinant hemagglutinin protein of rinderpest virus 474
expressed in insect cells induces cytotoxic T-cell responses in cattle. 475
Viral Immunol 2001;14:349–58. 476
[19] Sinnathamby G, Nayak R, Shaila MS. Mapping of T-helper 477
epitopes of rinderpest virus hemagglutinin protein. Viral Immunol 478
2001;14:83–92. 479
[20] Walsh EP, Baron MD, Anderson J, Barrett T. Development of a 480
genetically marked recombinant rinderpest vaccine expressing green 481
fluorescent protein. J Gen Virol 2000;81:709–18. 482
[21] Wigdorovitz A, Carrillo C, Dus Santos MJ, Trono K, Peralta A, 483
Gomez MC, et al. Induction of a protective antibody response to 484
foot and mouth disease virus in mice following oral or parenteral 485
immunization with alfalfa transgenic plants expressing the viral 486
structural protein VP1. Virology 1999;255:347–53. 487
[22] Gomez N, Wigdorovitz A, Castanon S, Gil F, Ordas R, Borca 488
MV, et al. Oral immunogenicity of the plant-derived spike protein 489
from swine-transmissible gastroenteritis coronavirus. Arch Virol 490
2000;145:1725–32. 491
[23] Khandelwal A, Lakshmi Sita G, Shaila MS. Expression of 492
hemagglutinin protein of rinderpest virus in transgenic tobacco and 493
immunogenicity of plant-derived protein in a mouse model. Virology, 494
in press. 495
[24] Plowright W, Ferris RD. Cytopathogenicity of rinderpest virus in 496
tissue culture. Nature 1957;179:316. 497
[25] Naik S, Shaila MS. Characterization of membrane-bound and 498
membrane anchor-less forms of hemagglutinin glycoprotein of 499
rinderpest virus expressed by baculovirus recombinants. Virus Genes 500
1997;14(2):95–104. 501
[26] Mitra-Kaushik S, Nayak R, Shaila MS. Identification of a cytotoxic 502
T-cell epitope on the recombinant nucleocapsid proteins of rinderpest 503
and peste des petits ruminants viruses presented as assembled 504
nucleocapsids. Virology 2001;279:210–20. 505
[27] Renukaradhya GJ, Mitra-Kaushik S, Sinnathamby G, Rajasekhar M, 506
Shaila MS. Mapping of B cell epitopes of hemagglutinin protein of 507
rinderpest virus. Virology 2002;298(2):214–23. 508
[28] Devirddy LR, Raghavan R, Ramachandran S, Subbarao SM. 509
Protection of rabbits against lapinized rinderpest virus with purified 510
envelope glycoproteins of peste des petits ruminants and rinderpest 511
viruses. Acta Virol 1998;42(5):299–306. 512
[29] McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, 513
Dietzschold B, et al. Expression of rabies virus glycoprotein in 514
transgenic tomatoes. Biotechnology 1995;13:1484–7. 515
[30] Anderson J, McKay JA. The detection of antibodies against peste 516
des petits ruminants virus in cattle, sheep and goats and the possible 517
implications to rinderpest control programmes. Epidemiol Infect 518
1994;112:225–31. 519
[31] Reed LJ, Muench H. A simple method of estimating 50% endpoints. 520
Am J Hyg 1938;27(3):493–7. 521
[32] Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, 522
Artnzen CJ. Immunogenicity in humans of a recombinant bacterial 523
antigen delivered in a transgenic potato. Nat Med 1998;4:607–9. 524
[33] Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen 525
CJ. Human immune responses to a novel Norwalk virus vaccine 526
delivered in transgenic potatoes. J Infect Dis 2000;182(1):302–5. 527
[34] Huang Z, Dry I, Webster D, Strugnell R, Wesselingh S. Plant-derived 528
measles virus hemagglutinin induces neutralizing antibodies in mice. 529
Vaccine 2001;19:2163–71. 530
[35] Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala 531
Y. Oral immunization with hepatitis B surface antigen expressed 532
in transgenic plants. Proc Natl Acad Sci USA 2001;98(20):11539– 533
44.
UN
CO
RR
EC
TE
D 
PR
OO
F
8 A. Khandelwal et al. / Vaccine 3812 (2003) 1–8
[36] Modelska A, Dietzschold B, Sleysh N, Fu ZF, Steplewski K, Hooper534
DC, et al. Immunization against rabies with plant-derived antigen.535
Proc Natl Acad Sci USA 1998;95(5):2481–5.536
[37] de Aizpurua HJ, Russell-Jones GJ. Oral vaccination. Identification537
of classes of proteins that provoke an immune response upon oral538
feeding. J Exp Med 1988;167:440–51.
[38] Lavelle EC, Grant G, Pusztai A, Pfuller U, O’Hagan DT. The 539
identification of plant lectins with mucosal adjuvant activity. 540
Immunology 2002;102:77–86. 541
[39] Barrett T, Rossiter PB. Rinderpest: the disease and its 542
impact on humans and animals. Adv Virus Res 1999;53:89– 543
110. 544
